甲羟孕酮减轻化疗患者骨髓抑制临床观察  

Clinical Observation of Medroxyprogesterone Acetate to Palliate Myelosuppression after Chemotherapy

作　　者：何朗[1,2] 李光明[1,2] 文世民[1,2] 任大成[1,2] 郭翠华[1,2] 别俊[1,2] 胡欣[1,2] 潘荣强[1,2] 

机构地区：[1]川北医学院第二临床医学院 [2]南充市中心医院肿瘤中心,四川南充637000

出　　处：《华西医学》2010年第5期865-867,共3页West China Medical Journal

基　　金：川北医学院苗圃基金项目[苗圃(08)临-15)]

摘　　要：目的观察消化道肿瘤患者服用甲羟孕酮(medroxyprogesterone acetate,MPA)对化疗后骨髓抑制的影响。方法 2008年11月2009年8月,将接受化疗的消化道肿瘤患者共100例随机分为治疗组(MPA加化疗组,54例)及对照组(单纯化疗组,46例),2周期化疗后评价骨髓抑制状况和生活质量变化。结果治疗组和对照组化疗后白细胞、血红蛋白和血小板Ⅰ～Ⅱ度骨髓抑制发生率没有差异(P>0.05),但治疗组Ⅲ～Ⅳ度骨髓抑制发生率低于对照组,KPS评分改善率高于对照组(P<0.05)。未见明显不良反应。结论 MPA可有效减轻化疗后骨髓抑制。Objective To observe the effect of medroxyprogesterone acetate （MPA） combined with chemotherapy on the myelosuppression of patients with enteron malignancy. Methode From November 2008 to August 2009, 100 patients with enteron malignancy were randomly divided into the trial group （MPA combined with chemotherapy, n=54） and the control group （chemotherapy, n=46）, and the effects of myelosuppression and quality of life were evaluated after two cycles. Results The incidence of degree one to two myelosuppression had no statistical significance （P0.05） in leucocyte, hemoglobin and thrombocyte between the trial group and the control group, but degree three to four myelosuppression was significantly lower and the improvement rate of KPS was significantly greater in the trial group compared with the control group after chemotherapy, respectively （P0.05）. There was no obvious side reaction of MPA in trials. Conclusion MPA could effectively palliate the myelosuppression in chemotherapy.

关 键 词：甲羟孕酮 化疗 骨髓抑制 

分 类 号：R473.73[医药卫生—护理学]